SIRION BIOTECH GmbH 19. Dezember 2013

Viral vectors made in human expression sytem

SIRION Biotech licences rights to CEVEC Pharmaceuticals' immortalized suspension cells derived from primary human amniocytes for its range of viral vectors Munich, Cologne, SIRION Biotech announced today it is now providing viral vectors for preclinical use to be expressed in CEVEC’s CAP®-Technology. CAP® cell lines are designed for stable and transient protein production and achieve highest protein yields with authentic human glycosylation patterns. Adenovirus and AAV vectors expressed in CAP® cell lines not only allow for higher yields, they also meet most stringent safety requirements when it comes to material to be used for clinical trials.
SIRION Biotech GmbH bietet kundenspezifische Engineering- und Fertigungsdienstleistungen für virale Vektoren für die Life-Sciences-Indus... [mehr]